Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 13, 2025 09:00 ET | Source: AtaiBeckley N.V.

AtaiBeckley to Participate in the Jefferies Global Healthcare Conference in London

NEW YORK and AMSTERDAM, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Atai Beckley N.V. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biopharmaceutical company on a mission to transform patient...
November 13, 2025 09:00 ET | Source: NeOnc Technologies Holdings, Inc.

NeOnc Technologies Completes Enrollment in Pivotal NEO100 Phase2a Trial for IDH-1 mutant Recurrent High‑Grade Glioma and Expects Interim Data Readout in SixMonths (Q22026)

CALABASAS, Calif., Nov. 13, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a multi-Phase 2 clinical-stage biopharmaceutical company pioneering...
November 13, 2025 08:36 ET | Source: Bleichmar Fonti & Auld

MLTX ALERT: Did MoonLake Immunotherapeutics Mislead Investors? BFA Law Reminds Investors with Losses of the Upcoming December 15 Court Deadline

MoonLake Immunotherapeutics investors that lost money are notified to contact BFA before the December 15, 2025 securities fraud class action deadline.
November 13, 2025 08:25 ET | Source: Candel Therapeutics

Candel Therapeutics Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights

Presented new subgroup analyses from phase 3 clinical trial of CAN-2409 in localized prostate cancer at the American Society for Radiation Oncology (ASTRO) 2025 meeting, demonstrating improved...
November 13, 2025 08:00 ET | Source: Monopar Therapeutics Inc.

Monopar Therapeutics Reports Third Quarter 2025 Financial Results and Recent Developments

WILMETTE, Ill., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical‐stage biopharmaceutical company developing innovative treatments...
November 13, 2025 08:00 ET | Source: Clene Inc.

Clene Reports Third Quarter 2025 Financial Results and Recent Operating Highlights

As the U.S. Food and Drug Administration (FDA) proposed, Clene is concluding analyses of its ALS biomarker data with completion planned shortly The FDA advised Clene to request a Type C meeting to...
November 13, 2025 08:00 ET | Source: Arcutis Biotherapeutics, Inc.

Arcutis Completes Enrollment in INTEGUMENT-INFANT Phase 2 Study Evaluating ZORYVE® (roflumilast) Cream 0.05% in Infants with Atopic Dermatitis

Arcutis Completes Enrollment in INTEGUMENT-INFANT Phase 2 Study Evaluating ZORYVE® (roflumilast) Cream 0.05% in Infants with Atopic Dermatitis
November 13, 2025 08:00 ET | Source: MeiraGTx

MeiraGTx Reports Third Quarter 2025 Financial and Operational Results

Entered into broad strategic collaboration with Eli Lilly and Company (“Lilly”) in the area of ophthalmology, granting Lilly worldwide exclusive rights to the Company’s AAV-AIPL1 program for...
November 13, 2025 08:00 ET | Source: Matisse Pharmaceuticals

Matisse Pharmaceuticals successfully completes study with prolonged infusion of M6229 in healthy volunteers

Successful phase 1 with prolonged infusion duration could offer an effective solution for irreversibly stopping harmful inflammatory responses in sepsis.
November 13, 2025 07:45 ET | Source: Vivani Medical, Inc.

Vivani Medical Provides Business Update and Reports Third Quarter 2025 Financial Results

Company plans to initiate Phase 1 clinical study of semaglutide implant for chronic weight management in the first half of 2026 and parallel investments in studies to enable rapid initiation of Phase...